• Shan Yan, Xuefeng Zhang, Xiaoyi Tian, Jiangjin Li, Ling Zhuang, Xiwen Zhang, and Yicheng Jiang.
• Department of Cardiology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an 223300, China.
• Zhonghua Yi Xue Za Zhi. 2014 Jan 7; 94 (1): 10-3.

ObjectiveTo evaluate the prognosis value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for non-ST-elevation acute coronary syndrome (NSTEACS).MethodsA total of 277 patients (212 male, mean age 59 ± 12 years) with NSTEACS underwent successful PCI. The patients were then divided into MACE group and non-MACE group. Patients were divided into 4 groups according to the level of cystatinC : Q1 (<0.78 mg/L), Q2 (0.78-0.93 mg/L), Q3 (0.94-1.11 mg/L), and Q4 ( ≥ 1.12 mg/L) . Risk factors for MACE were analyzed by Cox regression analysis.ResultsThe plasma Cys-C level were higher in MACE group than in non-MACE group(P < 0.05). The areas under ROC curve of Cys-C, cTnI, hsCRP an CK-MB to predict cardiac event were 0.737,0.630,0.692 and 0.650 respectively. After a follow-up of 1 year, the MACE in the Q2, Q3, and Q4 groups was higher than in the Q1 group (Logrank = 23.751, P < 0.01). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events (P < 0.01).ConclusionHigh plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with NSTEACS treated with PCI.

14 keywords...

hide…